Abstract: An in vitro method to discover or screen various an agent capable of modulating onset or progression of hepatic metastasis through inhibition or suppression of genes associated with prometastatic reaction in hepatic tissue. The method comprises preparing a primary mix-culture of hepatic parenchymal and non-parenchymal cells, exposing cells to colorectal cancer cells to induce a prometastatic reaction; the exposing the cells to the therapeutic agent to be screened, and then measuring gene expression profiles of cells exposed to the agent, and finally comparing the measured gene expression profile to a reference gene expression profile whereby to determine if the agent has a positive effect on inhibiting or suppressing metastatic reaction.

Abstract: Rule-based apparatus and kit to detect metastatic cancer in a patient having a colorectal tumor. Apparatus has inputs to receive patient data comprising expression levels of genes from hepatic tissue, a memory that stores reference values of corresponding genes of persons free of colorectal tumors, a processor that interprets significance of overexpression and/or underexpression of selected patient data genes relative to reference values, and an output responsive to the processor to produce an indication confirming or annulling hepatic metastasis. Specific genes in questions include group 1 genes (PRDX4, CRP, ID1, MT1E, TNFSF14, MRC1, ICAM1, IL18, IL10, TFN) and group 2 genes (NGF, EPHA1, ERBB2IP, SDC1, COL18A1, KNG1, ADH1 B, CYP2E1). Analysis may be performed on protein signatures of genes rather than genes themselves.

Abstract: A method of detecting prometastatic cancer activity in the liver of a patient suffering from colorectal cancer, as well as a method of diagnosing and treating colorectal cancer according to primary tumor location, based on divergent expression levels and functional classification of specific genes in tumor unaffected hepatic tissue. Specific genes include statistically significant ones of group 1 genes PRDX4, CRP, ID1, MT1E, TNFSF14, MRC1, ICAM1, IL18, IL10, TFN; group 2 genes NGF, EPHA1, ERBB2IP, SDC1, COL18A1, KNG1, ADH1B, CYP2E1; and group 3 genes HP, VTN, RPS27, RPL23, GAPDH, TXN, VEGFA, CEACAM1, IGF1, TGFB1, DDR2, NOS2, and BMP7.

Abstract: The present invention relates to the use of an antifungal agent or of a compound capable of binding to a mannoprotein and blocking the binding of said mannoprotein to an endothelial cell receptor, in the preparation of a pharmaceutical composition for treating a disease associated to an unwanted cell adhesion. Likewise, the present invention also contemplates methods aimed at identifying a compound potentially useful for preventing and/or treating a disease associated to an unwanted cell adhesion, for predicting the probability of a patient suffering from cancer to suffer from metastasis and for designing a personalized therapy for a patient suffering from cancer.

Abstract: This invention is related to new nitrogenated trans-stilbene compounds, more specifically, imine, pyrrole and indole derivatives, with procedures for the preparation and use thereof as pharmaceutical compositions for the treatment and/or chemoprevention of those mammalian diseases such as cancer, fibrosclerosis and acute/chronic inflammation, graft-versus-host reaction, ischemic-reperfusion tissue injury in stroke and heart attack, neurodegeneration, and during organ transplantation, whose pathogenic and pathophysiological mechanisms depend on or are significantly contributed by undesirable oxidative stress, angiogenic and proliferative responses.

Abstract: The invention relates to the treatment of disorders or diseases mediated by LFA-1/ICAM-1 molecular interaction. This is based on the use of novel chemical compounds capable of inhibiting said interaction, and more particularly, to pharmaceutical compositions containing these compounds.

Abstract: This invention is related to new nitrogenated trans-stilbene compounds, more specifically, imine, pyrrole and indole derivatives, with procedures for the preparation and use thereof as pharmaceutical compositions for the treatment and/or chemoprevention of those mammalian diseases such as cancer, fibrosclerosis and acute/chronic inflammation, graft-versus-host reaction, ischemic-reperfusion tissue injury in stroke and heart attack, neurodegeneration, and during organ transplantation, whose pathogenic and pathophysiological mechanisms depend on or are significantly contributed by undesirable oxidative stress, angiogenic and proliferative responses.

Abstract: This invention is related to new nitrogenated trans-stilbene analog compounds, more specifically, imine, pyrrol and Indole derivatives, with procedures for the preparation and use thereof as pharmaceutical compositions for the treatment and/or chemoprevention of those mammalian diseases such as cancer, fibrosclerosis and acute/chronic inflammation, graft-versus-host reaction, ischemic-reperfusion tissue injury in stroke and heart attack, neurodegeneration, and during organ transplantation, whose pathogenic and pathophysiological mechanisms depend on or are significantly contributed by undesirable oxidative stress, angiogenic and proliferative responses.

Abstract: The present invention is a chemical composition including: Use of the compound with the chemical formula can be applied in pharmaceutical compositions for the treatment of psoriasis.

Abstract: This invention relates to nitroproline derivative compounds and procedures for their preparation and the preparation of pharmaceutical compositions containing the compounds. The invention also relates to the administration of compounds of the invention as agents for the treatment of mammalian diseases whose pathogenic and pathophysiological mechanisms depend on or are significantly contributed by undesirable cellular and molecular activities or responses induced by integrin-dependent molecular interactions.

Abstract: The invention relates to the treatment of disorders or diseases mediated by LFA-1/ICAM-1 molecular interaction. This is based on the use of novel chemical compounds capable of inhibiting said interaction, and more particularly, to pharmaceutical compositions containing these compounds.